{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:31:00Z","timestamp":1792373460987,"version":"4.4.0"},"reference-count":87,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":945,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,16]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>During the past decade several notable viruses have suddenly emerged from obscurity or anonymity to become serious global health threats, provoking concern regarding their sustained epidemic transmission in immunologically naive human populations. With each new threat comes the call for rapid vaccine development. Indeed, vaccines are considered a critical component of disease prevention for emerging viral infections because, in many cases, other medical options are limited or non-existent, or that infections result in such a rapid clinical deterioration that the effectiveness of therapeutics is limited. While classic approaches to vaccine development are still amenable to emerging viruses, the application of molecular techniques in virology has profoundly influenced our understanding of virus biology, and vaccination methods based on replicating, attenuated and non-replicating virus vector approaches have become useful vaccine platforms. Together with a growing understanding of viral disease emergence, a range of vaccine strategies and international commitment to underpin development, vaccine intervention for new and emerging viruses may become a possibility.<\/jats:p>","DOI":"10.1111\/cei.13295","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T02:02:04Z","timestamp":1555466524000},"page":"157-166","source":"Crossref","is-referenced-by-count":107,"title":["Emerging viruses and current strategies for vaccine intervention"],"prefix":"10.1093","volume":"196","author":[{"given":"B","family":"Afrough","sequence":"first","affiliation":[{"name":"Virology and Pathogenesis Laboratory, National Infection Service, Public Health England, Salisbury, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Dowall","sequence":"additional","affiliation":[{"name":"Virology and Pathogenesis Laboratory, National Infection Service, Public Health England, Salisbury, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Hewson","sequence":"additional","affiliation":[{"name":"Virology and Pathogenesis Laboratory, National Infection Service, Public Health England, Salisbury, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,16]]},"reference":[{"key":"2022011422552996500_cei13295-bib-0001","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/nature06536","article-title":"Global trends in emerging infectious diseases","volume":"51","author":"Jones","year":"2008","journal-title":"Nature"},{"key":"2022011422552996500_cei13295-bib-0002","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tree.2005.02.009","article-title":"Emerging pathogens: the epidemiology and evolution of species jumps","volume":"20","author":"Woolhouse","year":"2005","journal-title":"Trends Ecol Evol"},{"key":"2022011422552996500_cei13295-bib-0003","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1863-2378.2008.01218.x","article-title":"Bats and emerging zoonoses: henipaviruses and SARS","volume":"56","author":"Field","year":"2009","journal-title":"Zoonoses Publ Health"},{"key":"2022011422552996500_cei13295-bib-0004","doi-asserted-by":"crossref","first-page":"14830","DOI":"10.1038\/srep14830","article-title":"Spillover and pandemic properties of zoonotic viruses with high host plasticity","volume":"5","author":"Kreuder Johnson","year":"2015","journal-title":"Sci Rep"},{"key":"2022011422552996500_cei13295-bib-0005","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(12)61678-X","article-title":"Ecology of zoonoses: natural and unnatural histories","volume":"380","author":"Karesh","year":"2012","journal-title":"Lancet"},{"key":"2022011422552996500_cei13295-bib-0006","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1056\/NEJMsr1513109","article-title":"After Ebola in West Africa \u2013 unpredictable risks, preventable epidemics","volume":"375","author":"WHO Ebola Response Team","year":"2016","journal-title":"N Engl J Med"},{"key":"2022011422552996500_cei13295-bib-0007","author":"A Research and Development Blueprint for Action to Prevent Epidemics"},{"key":"2022011422552996500_cei13295-bib-0008","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S1357-4310(99)01622-6","article-title":"RNA viruses: emerging vectors for vaccination and gene therapy","volume":"6","author":"Hewson","year":"2000","journal-title":"Mol Med Today"},{"key":"2022011422552996500_cei13295-bib-0009","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.immuni.2010.10.004","article-title":"Immunologic basis of vaccine vectors","volume":"33","author":"Liu","year":"2010","journal-title":"Immunity"},{"key":"2022011422552996500_cei13295-bib-0010","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.coviro.2011.07.009","article-title":"Viruses \u2013 from pathogens to vaccine carriers","volume":"1","author":"Small","year":"2011","journal-title":"Curr Opin Virol"},{"key":"2022011422552996500_cei13295-bib-0011","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.coi.2011.03.006","article-title":"Viral vectors as vaccine platforms: deployment in sight","volume":"23","author":"Rollier","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"2022011422552996500_cei13295-bib-0012","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1586\/14760584.2015.965690","article-title":"Self-replicating alphavirus RNA vaccines","volume":"14","author":"Ljungberg","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"2022011422552996500_cei13295-bib-0013","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1016\/j.vaccine.2017.04.085","article-title":"Rapid development of vaccines against emerging pathogens: the replication-deficient simian adenovirus platform technology","volume":"35","author":"Gilbert","year":"2017","journal-title":"Vaccine"},{"key":"2022011422552996500_cei13295-bib-0014","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3390\/v7041726","article-title":"The evolution of poxvirus vaccines","volume":"4","author":"S\u00e1nchez-Sampedro","year":"2015","journal-title":"Viruses"},{"key":"2022011422552996500_cei13295-bib-0015","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1016\/j.vaccine.2016.06.071","article-title":"Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: standardized template with key considerations for a risk\/benefit assessment","volume":"34","author":"Clarke","year":"2016","journal-title":"Vaccine"},{"key":"2022011422552996500_cei13295-bib-0016","first-page":"199","article-title":"Rhabdoviruses as vaccine vectors: from initial development to clinical trials. Biology, pathogenesis of rhabdo-, filoviruses","author":"John","year":"2015"},{"key":"2022011422552996500_cei13295-bib-0017","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1128\/JVI.73.5.3723-3732.1999","article-title":"Attenuated vesicular stomatitis viruses as vaccine vectors","volume":"73","author":"Roberts","year":"1999","journal-title":"J Virol"},{"key":"2022011422552996500_cei13295-bib-0018","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1084\/jem.20072290","article-title":"Yellow fever and Max Theiler: the only Nobel Prize for a virus vaccine","volume":"204","author":"Norrby","year":"2007","journal-title":"J Exp Med"},{"key":"2022011422552996500_cei13295-bib-0019","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0065-3527(03)60009-6","article-title":"Pathogenesis and pathophysiology of yellow fever","volume":"60","author":"Monath","year":"2003","journal-title":"Adv Virus Res"},{"key":"2022011422552996500_cei13295-bib-0020","first-page":"285","article-title":"Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation","volume":"1","author":"Rice","year":"1989","journal-title":"New Biol"},{"key":"2022011422552996500_cei13295-bib-0021","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.4161\/hv.28117","article-title":"The yellow fever 17D virus as a platform for new live attenuated vaccines","volume":"10","author":"Bonaldo","year":"2014","journal-title":"Hum Vacc Immunother"},{"key":"2022011422552996500_cei13295-bib-0022","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1016\/j.vaccine.2011.06.094","article-title":"From research to hase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine","volume":"29","author":"Guy","year":"2011","journal-title":"Vaccine"},{"key":"2022011422552996500_cei13295-bib-0023","doi-asserted-by":"crossref","first-page":"10310","DOI":"10.1128\/JVI.05252-11","article-title":"Creation of a recombinant Rift Valley fever virus with a two-segmented genome","volume":"85","author":"Brennan","year":"2011","journal-title":"J Virol"},{"key":"2022011422552996500_cei13295-bib-0024","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.virol.2008.04.020","article-title":"IRES dependent replication of Venezuelan equine encephalitis virus makes it highly attenuated and incapable of replicating in mosquito cells","volume":"377","author":"Volkova","year":"2008","journal-title":"Virology"},{"key":"2022011422552996500_cei13295-bib-0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.virol.2012.11.013","article-title":"IRES-based Venezuelan equine encephalitis vaccine candidate elicits protective immunity in mice","volume":"437","author":"Rossi","year":"2013","journal-title":"Virology"},{"key":"2022011422552996500_cei13295-bib-0026","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1128\/JVI.80.7.3259-3272.2006","article-title":"Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region","volume":"80","author":"Burns","year":"2006","journal-title":"J Virol"},{"key":"2022011422552996500_cei13295-bib-0027","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1128\/JVI.03401-14","article-title":"Development of live attenuated arenavirus vaccines based on codon deoptimization","volume":"89","author":"Cheng","year":"2015","journal-title":"J Virol"},{"key":"2022011422552996500_cei13295-bib-0028","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"2022011422552996500_cei13295-bib-0029","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what\u2019s important?","volume":"10","author":"Fausther-Bovendo","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"2022011422552996500_cei13295-bib-0030","doi-asserted-by":"crossref","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLOS ONE"},{"key":"2022011422552996500_cei13295-bib-0031","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/319549a0","article-title":"Recombinant vaccinia viruses as vaccines","volume":"319","author":"Brown","year":"1986","journal-title":"Nature"},{"key":"2022011422552996500_cei13295-bib-0032","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1055\/s-0028-1108143","article-title":"MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) [author\u2019s translation]","volume":"99","author":"Stickl","year":"1974","journal-title":"Dtsch Med Wochenschr"},{"key":"2022011422552996500_cei13295-bib-0033","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2174\/156652321306140103221941","article-title":"Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors","volume":"13","author":"Goossens","year":"2013","journal-title":"Curr Gene Ther"},{"key":"2022011422552996500_cei13295-bib-0034","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0378-1119(83)90163-4","article-title":"Infectious poxvirus vectors have capacity for at least 25000 base pairs of foreign DNA","volume":"25","author":"Smith","year":"1983","journal-title":"Gene"},{"key":"2022011422552996500_cei13295-bib-0035","doi-asserted-by":"crossref","first-page":"19ra12","DOI":"10.1126\/scitranslmed.3000490","article-title":"Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass","volume":"2","author":"Alcock","year":"2010","journal-title":"Sci Transl Med"},{"key":"2022011422552996500_cei13295-bib-0036","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development","volume":"97","author":"Volz","year":"2017","journal-title":"Adv Virus Res"},{"key":"2022011422552996500_cei13295-bib-0037","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/02648725.2018.1471643","article-title":"Vaccinia-based vaccines to biothreat and emerging viruses","volume":"34","author":"Nagata","year":"2018","journal-title":"Biotechnol Genet Eng Rev"},{"key":"2022011422552996500_cei13295-bib-0038","doi-asserted-by":"crossref","first-page":"e91516","DOI":"10.1371\/journal.pone.0091516","article-title":"A novel vaccine against Crimean\u2013Congo haemorrhagic fever protects 100% of animals against lethal challenge in a mouse model","volume":"9","author":"Buttigieg","year":"2014","journal-title":"PLOS ONE"},{"key":"2022011422552996500_cei13295-bib-0039","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.coviro.2017.11.012","article-title":"Understanding orthopoxvirus host range and evolution: from the enigmatic to the usual suspects","volume":"28","author":"Reynolds","year":"2018","journal-title":"Curr Opin Virol"},{"key":"2022011422552996500_cei13295-bib-0040","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fpubh.2018.00241","article-title":"Emergence of monkeypox as the most important orthopoxvirus infection in humans","volume":"4","author":"Sklenovsk\u00e1","year":"2018","journal-title":"Front Public Health"},{"key":"2022011422552996500_cei13295-bib-0041","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1126\/science.8073288","article-title":"Engineering poliovirus as a vaccine vector for the expression of diverse antigens","volume":"265","author":"Andino","year":"1994","journal-title":"Science"},{"key":"2022011422552996500_cei13295-bib-0042","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1128\/JVI.73.5.3854-3865.1999","article-title":"Selection of RNA replicons capable of persistent noncytopathic replication in mammalian cells","volume":"73","author":"Frolov","year":"1999","journal-title":"J Virol"},{"key":"2022011422552996500_cei13295-bib-0043","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/vaccines4040039","article-title":"Replicon RNA viral vectors as vaccines","volume":"4","author":"Lundstrom","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"2022011422552996500_cei13295-bib-0044","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1093\/infdis\/jiy123","article-title":"Use of a scalable replicon-particle vaccine to protect against lethal lassa virus infection in the guinea pig model","volume":"217","author":"Kainulainen","year":"2018","journal-title":"J Infect Dis"},{"key":"2022011422552996500_cei13295-bib-0045","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1128\/JVI.00074-09","article-title":"Replication-deficient ebolavirus as a vaccine candidate","volume":"83","author":"Halfmann","year":"2009","journal-title":"J Virol"},{"key":"2022011422552996500_cei13295-bib-0046","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1128\/JVI.07104-11","article-title":"Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge","volume":"86","author":"Dodd","year":"2012","journal-title":"J Virol"},{"key":"2022011422552996500_cei13295-bib-0047","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Rold\u00e3o","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"2022011422552996500_cei13295-bib-0048","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2174\/157016210791208659","article-title":"Virus-like particles as particulate vaccines","volume":"8","author":"Buonaguro","year":"2010","journal-title":"Curr HIV Res"},{"key":"2022011422552996500_cei13295-bib-0049","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.addr.2014.10.023","article-title":"Formulation and stabilization of recombinant protein based virus-like particle vaccines","volume":"93","author":"Jain","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"2022011422552996500_cei13295-bib-0050","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/emmm.201403876","article-title":"Vaccines for the 21st century","volume":"6","author":"Delany","year":"2014","journal-title":"EMBO Mol Med"},{"key":"2022011422552996500_cei13295-bib-0051","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1089\/hum.2006.17.1051","article-title":"DNA vaccines: recent developments and future possibilities","volume":"17","author":"Liu","year":"2006","journal-title":"Hum Gene Ther"},{"key":"2022011422552996500_cei13295-bib-0052","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nbt0704-799","article-title":"DNA vaccines \u2013 back in the saddle again?","volume":"22","author":"Powell","year":"2004","journal-title":"Nat Biotechnol"},{"key":"2022011422552996500_cei13295-bib-0053","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/infdis\/jir054","article-title":"A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a Phase I clinical trial","volume":"203","author":"Ledgerwood","year":"2011","journal-title":"J Infect Dis"},{"key":"2022011422552996500_cei13295-bib-0054","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1128\/CVI.00162-06","article-title":"A DNA vaccine for Ebola virus is safe and immunogenic in a Phase I clinical trial","volume":"13","author":"Martin","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"2022011422552996500_cei13295-bib-0055","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1016\/j.vaccine.2011.04.043","article-title":"A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(S\/S) mice upon lethal virus challenge","volume":"29","author":"Boshra","year":"2011","journal-title":"Vaccine"},{"key":"2022011422552996500_cei13295-bib-0056","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.vaccine.2011.10.085","article-title":"Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine","volume":"30","author":"Porter","year":"2012","journal-title":"Vaccine"},{"key":"2022011422552996500_cei13295-bib-0057","doi-asserted-by":"crossref","first-page":"e928","DOI":"10.1371\/journal.pntd.0000928","article-title":"A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates","volume":"5","author":"Mallilankaraman","year":"2011","journal-title":"PLOS Negl Trop Dis"},{"key":"2022011422552996500_cei13295-bib-0058","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nrd2224","article-title":"More than one reason to rethink the use of peptides in vaccine design","volume":"6","author":"Purcell","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"2022011422552996500_cei13295-bib-0059","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.vaccine.2011.11.002","article-title":"HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX((R)) B\/E","volume":"30","author":"Paris","year":"2012","journal-title":"Vaccine"},{"key":"2022011422552996500_cei13295-bib-0060","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00262-003-0480-x","article-title":"The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy","volume":"53","author":"Singh-Jasuja","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"2022011422552996500_cei13295-bib-0061","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/icb.2010.65","article-title":"Innovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses","volume":"89","author":"Sirskyj","year":"2011","journal-title":"Immunol Cell Biol"},{"key":"2022011422552996500_cei13295-bib-0062","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.vaccine.2015.01.040","article-title":"A bioinformatics tool for epitope-based vaccine design that accounts for human ethnic diversity: application to emerging infectious diseases","volume":"33","author":"Oyarzun","year":"2015","journal-title":"Vaccine"},{"key":"2022011422552996500_cei13295-bib-0063","first-page":"145","article-title":"Polio vaccines: WHO position paper","volume":"91","author":"World Health Organization (WHO)","year":"2016","journal-title":"Wkly Epidemiol Rec"},{"key":"2022011422552996500_cei13295-bib-0064","article-title":"An overview of the immunogenicity and effectiveness of current human rabies vaccines administered by intradermal route","author":"Denis","year":"2018","journal-title":"Vaccine"},{"key":"2022011422552996500_cei13295-bib-0065","doi-asserted-by":"crossref","first-page":"B163","DOI":"10.1016\/j.vaccine.2012.10.117","article-title":"A global regulatory science agenda for vaccines","volume":"31","author":"Elmgren","year":"2013","journal-title":"Vaccine"},{"key":"2022011422552996500_cei13295-bib-0066","doi-asserted-by":"crossref","first-page":"13934","DOI":"10.1128\/JVI.79.22.13934-13942.2005","article-title":"A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses","volume":"79","author":"Lukashevich","year":"2005","journal-title":"J Virol"},{"key":"2022011422552996500_cei13295-bib-0067","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1371\/journal.pmed.0020183","article-title":"Development of a new vaccine for the prevention of Lassa fever","volume":"2","author":"Geisbert","year":"2005","journal-title":"PLOS Med"},{"key":"2022011422552996500_cei13295-bib-0068","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.vaccine.2010.11.079","article-title":"Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs","volume":"29","author":"Jiang","year":"2011","journal-title":"Vaccine"},{"key":"2022011422552996500_cei13295-bib-0069","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(87)90767-7","article-title":"Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guinea pigs against Lassafever","volume":"2","author":"Clegg","year":"1987","journal-title":"Lancet"},{"key":"2022011422552996500_cei13295-bib-0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.virol.2016.11.001","article-title":"Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein","volume":"501","author":"Cheng","year":"2017","journal-title":"Virology"},{"key":"2022011422552996500_cei13295-bib-0071","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/vaccines1030262","article-title":"Enhanced efficacy of a codon-optimized DNA vaccine encoding the glycoprotein precursor gene of Lassa virus in a guinea pig disease model when delivered by dermal electroporation","volume":"1","author":"Cashman","year":"2013","journal-title":"Vaccines (Basel)"},{"key":"2022011422552996500_cei13295-bib-0072","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1016\/j.vaccine.2008.07.057","article-title":"Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates","volume":"26","author":"Lukashevich","year":"2008","journal-title":"Vaccine"},{"key":"2022011422552996500_cei13295-bib-0073","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1080\/21645515.2017.1356500","article-title":"A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever","volume":"13","author":"Cashman","year":"2017","journal-title":"Hum Vaccine Immunother"},{"key":"2022011422552996500_cei13295-bib-0074","volume-title":"WHO publishes list of top emerging diseases likely to cause major epidemics","author":"World Health Organization (WHO)","year":"2015"},{"key":"2022011422552996500_cei13295-bib-0075","volume-title":"Global partnership launched to prevent epidemics with new vaccines","author":"Coalition for Epidemic Preparedness Innovations (CEPI)","year":"2017"},{"key":"2022011422552996500_cei13295-bib-0076","doi-asserted-by":"crossref","first-page":"8399","DOI":"10.1073\/pnas.1208059110","article-title":"Zoonosis emergence linked to agricultural intensification and environmental change","volume":"110","author":"Jones","year":"2013","journal-title":"Proc Nat Acad Sci USA"},{"issue":"4Suppl","key":"2022011422552996500_cei13295-bib-0077","first-page":"818","article-title":"Impact of vaccines and vaccination on global control of avian influenza","volume":"56","author":"Swayne","year":"2013","journal-title":"Avian Dis"},{"key":"2022011422552996500_cei13295-bib-0078","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fcimb.2012.00131","article-title":"Novel approaches to develop Rift Valley fever vaccines","volume":"2","author":"Indran","year":"2012","journal-title":"Front Cell Infect Microbiol"},{"key":"2022011422552996500_cei13295-bib-0079","doi-asserted-by":"crossref","first-page":"e0005126","DOI":"10.1371\/journal.pntd.0005126","article-title":"Serological and virological evidence of Crimean\u2013Congo haemorrhagic fever virus circulation in the human population of Borno State, Northeastern Nigeria","volume":"10","author":"Bukbuk","year":"2016","journal-title":"PLOS Negl Trop Dis"},{"key":"2022011422552996500_cei13295-bib-0080","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1128\/MMBR.00004-08","article-title":"Cross-species virus transmission and the emergence of new epidemic diseases","volume":"72","author":"Parrish","year":"2008","journal-title":"Microbiol Mol Biol Rev"},{"key":"2022011422552996500_cei13295-bib-0081","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s007050050669","article-title":"Isolation of an attenuated myxoma virus field strain that can confer protection against myxomatosis on contacts of vaccinates","volume":"145","author":"Barcena","year":"2000","journal-title":"Arch Virol"},{"key":"2022011422552996500_cei13295-bib-0082","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1297-9716-42-76","article-title":"The current status and future directions of myxoma virus, a master in immune evasion","volume":"42","author":"Spiesschaert","year":"2011","journal-title":"Vet Res"},{"key":"2022011422552996500_cei13295-bib-0083","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.vaccine.2005.07.070","article-title":"Replication and immunoactivity of the recombinant Peromyscus maniculatus cytomegalovirus expressing hantavirus G1 glycoprotein in vivo and in vitro","volume":"24","author":"Rizvanov","year":"2006","journal-title":"Vaccine"},{"key":"2022011422552996500_cei13295-bib-0084","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.vaccine.2015.03.029","article-title":"A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose","volume":"33","author":"Tsuda","year":"2015","journal-title":"Vaccine"},{"key":"2022011422552996500_cei13295-bib-0085","article-title":"Ebola: outbreaks cause crisis for great apes and humans","author":"Ghai","year":"2014"},{"key":"2022011422552996500_cei13295-bib-0086","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1586\/14760584.2016.1106942","article-title":"Self-disseminating vaccines for emerging infectious diseases","volume":"15","author":"Murphy","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"2022011422552996500_cei13295-bib-0087","doi-asserted-by":"crossref","first-page":"20161903","DOI":"10.1098\/rspb.2016.1903","article-title":"Eradicating infectious disease using weakly transmissible vaccines","volume":"283","author":"Nuismer","year":"2016","journal-title":"Proc R Soc B"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.13295","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/196\/2\/157\/42197335\/cei13295.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/196\/2\/157\/42197335\/cei13295.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T17:56:23Z","timestamp":1642182983000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/196\/2\/157\/6421395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,16]]},"references-count":87,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,4,16]]},"published-print":{"date-parts":[[2019,4,16]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.13295","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2019,4,16]]}}}